Quick Answer
Retatrutide is Eli Lilly’s investigational “triple agonist” that activates the GIP, GLP-1, and glucagon receptors at once, and it has produced the largest weight-loss numbers ever recorded for a drug in this class. It is not approved by any regulator anywhere in the world, so the only lawful way to access it is by enrolling in a clinical trial.
FDA Status
Investigational (Phase 3)
UK (MHRA)
Not authorised
Australia (TGA)
Not registered
Drug Class
GIP/GLP-1/glucagon agonist
Developer
Eli Lilly (LY3437943)
Human Evidence
Phase 2 + Phase 3 ongoing
What Is Retatrutide?
Retatrutide (development code LY3437943) is an investigational once-weekly injectable peptide developed by Eli Lilly for chronic weight management and related metabolic conditions. It is the most clinically advanced “triple agonist,” meaning a single molecule designed to activate three different gut and pancreatic hormone receptors simultaneously: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon (GCG) receptor.
It sits one generation beyond the drugs most people already recognise. Semaglutide targets a single receptor (GLP-1). Tirzepatide targets two (GIP and GLP-1). Retatrutide adds a third arm, glucagon receptor agonism, which is the feature that appears to push its results into new territory.
The bottom line: Retatrutide is the first triple GIP/GLP-1/glucagon agonist to reach late-stage human trials, and it remains an experimental drug rather than an approved medicine.
How Retatrutide Works
Retatrutide works by combining three complementary hormone signals that each push metabolism in the same direction but by different routes. The GLP-1 arm slows gastric emptying, enhances glucose-dependent insulin release, and acts on appetite centres in the brain to reduce food intake. The GIP arm adds a second insulin-sensitising signal and appears to improve how the body handles fat and glucose. These two mechanisms are shared with tirzepatide.
The third arm is what makes retatrutide distinct. Glucagon receptor agonism increases energy expenditure and stimulates the breakdown of stored fat, particularly in the liver. Glucagon is best known for raising blood sugar, which sounds counterproductive in a metabolic drug, but the GLP-1 and GIP components counterbalance that effect so glucose control is maintained while the metabolic-rate and fat-mobilising benefits remain. Eli Lilly researchers have publicly attributed the unusually high weight-loss results to exactly this addition of glucagon agonism on top of the GIP and GLP-1 actions.
In simple terms: GLP-1 and GIP reduce how much you eat and improve how you process food, while the glucagon arm increases how much energy you burn and how aggressively the body taps into fat stores, including liver fat. The combination is why retatrutide outperforms single- and dual-agonist drugs on average body-weight reduction in head-to-head-comparable trial data.
The bottom line: Adding glucagon receptor agonism to the GIP and GLP-1 mechanism is the defining feature that separates retatrutide from every approved obesity drug currently on the market.
What the Research Shows
Retatrutide is supported by completed Phase 2 human trials and an expanding Phase 3 programme, which places it on a far stronger evidence footing than most compounds discussed in the research-peptide space. Every figure below comes from registered clinical trials in humans, not from animal models or anecdotal reports.
The Phase 2 foundation (human RCT)
The landmark Phase 2 obesity trial was led by Ania M. Jastreboff of Yale and published in the New England Journal of Medicine in 2023. It enrolled 338 adults with obesity, or with overweight plus a weight-related condition, and ran for 48 weeks. At the highest dose, mean weight loss reached roughly 24.2 percent of body weight, an average of about 58 pounds, with every participant on the two highest doses achieving at least 5 percent loss. A separate Phase 2 trial in adults with type 2 diabetes, published in The Lancet in 2023, reported around 17 percent body-weight reduction at 36 weeks alongside large reductions in HbA1c.
The Phase 3 TRIUMPH programme (human RCT)
TRIUMPH is Lilly’s umbrella name for the Phase 3 programme, a set of large pivotal trials enrolling thousands of participants across obesity, diabetes, cardiovascular, sleep apnoea, and osteoarthritis populations. Two readouts have reported so far. In December 2025, TRIUMPH-4 (obesity plus knee osteoarthritis) reported weight loss of up to roughly 71 pounds together with a large reduction in osteoarthritis pain. In May 2026, Lilly released topline results from TRIUMPH-1, the pivotal general-obesity trial in 2,339 adults without diabetes.
| Trial | Population | Headline result | Evidence tier |
|---|---|---|---|
| Phase 2 (NEJM 2023) | 338 adults, obesity, no diabetes | ~24.2% weight loss at 48 weeks (12 mg) | Completed human RCT |
| Phase 2 T2D (Lancet 2023) | 281 adults, type 2 diabetes | ~17% weight loss + large HbA1c drop at 36 weeks | Completed human RCT |
| TRIUMPH-4 (Dec 2025) | Obesity + knee osteoarthritis | Up to ~71 lbs lost + reduced OA pain | Phase 3 topline |
| TRIUMPH-1 (May 2026) | 2,339 adults, obesity, no diabetes | 28.3% weight loss at 80 weeks (12 mg) | Phase 3 topline |
In TRIUMPH-1, participants on the top dose lost an average of 28.3 percent of body weight (around 70 pounds) over 80 weeks, with roughly 45 percent reaching at least 30 percent body-weight reduction and about 65 percent dropping below a BMI of 30. Those figures are large enough that commentators have begun comparing them with the results seen after bariatric surgery, a benchmark no obesity drug had previously approached.
Unlike most compounds covered on this site, retatrutide’s efficacy data come from large, randomised, placebo-controlled human trials run to regulatory standard, not from rodent studies or user reports. The evidence quality is genuinely high. The open question is long-term safety, which is exactly what the remaining Phase 3 readouts are designed to characterise.
The bottom line: Retatrutide has the strongest human efficacy data of any triple agonist in development, and its top-dose Phase 3 result outstrips every approved obesity drug.
No obesity drug had ever averaged more than a quarter of body weight lost in a Phase 3 trial. Retatrutide reset that ceiling.
Regulatory Status by Country
Retatrutide is not approved by any medicines regulator anywhere in the world. It is still an experimental drug, which means its only lawful use is within an authorised clinical trial. Eli Lilly has stated that a regulatory submission is anticipated during 2026 as the full Phase 3 data package matures, with market approval not expected before around 2027.
| Region | Regulator | Status |
|---|---|---|
| United States | FDA | Investigational only; submission anticipated 2026 |
| United Kingdom | MHRA | No marketing authorisation; not on NHS or private prescription |
| Australia | TGA | Not on the ARTG; not available by prescription |
Because it has no approval, retatrutide also sits outside the pharmacy compounding pathway, and any “research grade” retatrutide sold online is an unapproved substance of unverified identity, purity, and dose. For the country-specific legal detail, see our guides to US peptide legality, UK peptide legality, and Australian peptide law.
The bottom line: Retatrutide is legal to use only inside an approved clinical trial, and any consumer purchase of it is purchase of an unapproved, unregulated product.
Safety and Side Effects
In trials, retatrutide’s side-effect profile has been broadly consistent with the wider incretin drug class. The most common adverse events are gastrointestinal: nausea, vomiting, diarrhoea, and constipation, mostly mild to moderate and concentrated during dose escalation. Crucially, these effects scale with dose.
TRIUMPH-1 reported discontinuation due to adverse events rising with dose: roughly 4.1 percent on the lowest dose, 6.9 percent in the middle, and 11.3 percent on the highest, against about 4.9 percent on placebo. In other words, the biggest-effect dose also carried the highest dropout rate, a trade-off that future labelling and dose selection will have to address.
Beyond gastrointestinal effects, retatrutide inherits the safety considerations regulators apply across the GLP-1 receptor agonist class. These include a class warning regarding thyroid C-cell tumours observed in rodent studies, attention to acute pancreatitis and gallbladder events, and the more recently flagged risk of delayed gastric emptying affecting anaesthesia and surgery, which the UK’s MHRA and Australia’s TGA have both highlighted for incretin drugs. Because retatrutide is still in trials, its long-term safety, especially the consequences of sustained glucagon agonism, has not yet been fully characterised in humans.
The safety figures above describe supervised clinical-trial use of a defined, quality-controlled trial product. They do not transfer to unregulated “research” vials bought online, where identity, sterility, dose accuracy, and contaminant content are unverified and where there is no medical monitoring for the very adverse events the trials are designed to catch.
The bottom line: Retatrutide’s trial safety profile is dominated by dose-dependent gastrointestinal effects, but its long-term safety remains under active investigation.
How Retatrutide Compares
Retatrutide is best understood as the next step in a clear progression of incretin drugs, distinguished from its predecessors mainly by average weight loss in trials and by its triple-receptor mechanism.
| Compound | Receptors targeted | Approx. trial weight loss | Approval status |
|---|---|---|---|
| Semaglutide | GLP-1 only | ~15% | Approved |
| Tirzepatide | GIP + GLP-1 | ~20% | Approved |
| Retatrutide | GIP + GLP-1 + glucagon | ~24-28% | Investigational |
The percentages above are drawn from separate trials with different designs and populations, so they are indicative rather than a true head-to-head ranking. For a detailed breakdown of how retatrutide stacks up against the leading approved dual agonist, see our tirzepatide vs retatrutide comparison.
The bottom line: Retatrutide’s edge over approved drugs is its glucagon arm and its higher average trial weight loss, but it pays for that with the uncertainty of being unapproved.
Where Retatrutide Research Is Heading
Seven additional TRIUMPH Phase 3 readouts are expected through 2026, including TRIUMPH-2 in adults with obesity and type 2 diabetes and TRIUMPH-3 in adults with established cardiovascular disease, alongside studies of maintenance dose strategies and a separate large cardiovascular outcomes trial. These readouts will determine the breadth of conditions retatrutide is eventually approved for, and they will provide the longer-term safety data regulators require before any approval.
In the meantime, demand has outrun supply, and retatrutide has appeared on the gray market labelled as a “research” chemical. This is the central risk to be aware of: that product is unapproved, sold without medical oversight, and of unverified quality, and buying it is not the same as receiving the molecule studied in TRIUMPH. Anyone evaluating such sellers should read our guide on vetting peptide sellers first, and recognise that no certificate of analysis can substitute for regulatory approval.
The bottom line: The next year of TRIUMPH data will define retatrutide’s eventual approved uses, while the gray market remains an unregulated and risky shortcut around a drug that is not yet legally available.
Retatrutide is the most promising obesity drug in development and one of the least appropriate to source outside a trial, precisely because it is not finished being studied.
Medical disclaimer: This article is for general information only and is not medical advice. Retatrutide is an investigational drug that has not been approved by the FDA, MHRA, TGA, or any other regulator, and it is not a treatment you can lawfully obtain outside a clinical trial. Nothing here should be taken as guidance to obtain or use it. Decisions about weight management or any medical condition should be made with a qualified healthcare professional.